Early Discontinuation of Antibiotics in Pediatric Patients with Low- and High-Risk Febrile Neutropenia: A Single-Center Experience
- 10 September 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (9)
Abstract
Background: Maintaining broad-spectrum antibiotics until resolution of fever and recovery of absolute neutrophil count (ANC) has traditionally been the standard approach for pediatric patients with cancer and for hematopoietic stem-cell transplantation (HSCT) recipients who present with febrile neutropenia (FN). Recent studies in adults support the safety of discontinuing empiric antibiotic treatment (EAT) prior to ANC recovery. However, data in children remain limited. Methods: Retrospective study that included patients under 18 years of age with cancer and/or undergoing HSCT admitted with FN between June 2022 and August 2023, in whom EAT was discontinued prior to ANC ≥500/mm3. Patients already receiving antibiotics for a documented or suspected source of bacterial infection, sepsis, or admitted to pediatric intensive care unit (PICU) were excluded. We report the characteristics and clinical outcomes (readmission, new fever onset, and new infection) within 7 days of the discontinuation of EAT, as well as the 30-day PICU admission, infection-related mortality, and all-cause mortality rates. Findings: We included 97 episodes (65 patients) of FN, 47 (48.4%) occurred in children with hematologic disease (malignant or non-malignant), including patients who had received an HSCT (n = 8) and/or a chimeric antigen receptors T-cell therapy (n = 6). Fever lasted less than 24 h in 75.3% of episodes. Median EAT duration was 3 days (interquartile range [IQR]: 3-5). Absolute neutrophil count recovery occurred at a median of 4 days (IQR 2-12) after EAT discontinuation. Fever recurred in 11 episodes (11.3%) within 7 days from EAT discontinuation. An infectious cause was identified in 3/11 episodes (mild bacterial folliculitis, probable primary Cytomegalovirus infection, and invasive fungal infection, n = 1 each). No admissions to PICU or 30-day infection-related mortality were observed. Two patients died because of non-infectious causes. Conclusion: Early EAT discontinuation before ANC recovery in selected pediatric patients with FN, including high-risk patients, may reduce hospitalization and antibiotic exposure.Keywords
This publication has 23 references indexed in Scilit:
- Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trialeClinicalMedicine, 2025
- Safety of empirical antibiotic therapy discontinuing for fever of unknown origin during high-risk neutropenia in childrenJournal of Infection, 2024
- Short-Course Empiric Antibiotics in Children Undergoing Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2023
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantationThe Lancet Oncology, 2021
- 1228. The Role of Procalcitonin (PCT) and Lactic Acid in Febrile Neutropenic Cancer Patients in an Oncological Emergency CenterOpen Forum Infectious Diseases, 2020
- Early Discontinuation versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with Febrile Neutropenia, Before Recovery of Counts: A Randomized Controlled Trial (DALFEN Study)Indian Journal of Pediatrics, 2020
- Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancerCochrane Database of Systematic Reviews, 2019
- Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trialThe Lancet Haematology, 2017
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Fever in Immunocompromised PatientsNew England Journal of Medicine, 1999